Targeted 595 ‐gene genomic profiling demonstrates low tumor mutational burden in olfactory neuroblastoma

ConclusionTMB is a novel biomarker guiding the classification of neoplasms in the emerging era of immunotherapy. The characterization of ONB as a low ‐TMB pathology contributes to the overall taxonomy of all cancers and suggests limited utility of immunotherapy treatment.
Source: International Forum of Allergy and Rhinology - Category: Allergy & Immunology Authors: Tags: ORIGINAL ARTICLE Source Type: research